Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
7 January 2019 |
Main ID: |
EUCTR2014-003572-23-FR |
Date of registration:
|
26/06/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Transplantation of CordIn, stem cells from donated umbilical cord blood that were grown in a laboratory to expand their number, in patients with a kind of genetic defect that results in abnormal structure of one of the globin chains of the hemoglobin molecule
|
Scientific title:
|
Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies |
Date of first enrolment:
|
27/12/2017 |
Target sample size:
|
15 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003572-23 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: no Open: yes Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no
|
Phase:
|
Human pharmacology (Phase I): yes
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
France
|
Italy
|
United States
| | | | | |
Contacts
|
Name:
|
Clinical Trial department
|
Address:
|
5, Nahum Hafzadi, Beit Ofer
9548401
Jerusalem
Israel |
Telephone:
|
97226595666 |
Email:
|
|
Affiliation:
|
Gamida Cell Ltd |
|
Name:
|
Clinical Trial department
|
Address:
|
5, Nahum Hafzadi, Beit Ofer
9548401
Jerusalem
Israel |
Telephone:
|
97226595666 |
Email:
|
|
Affiliation:
|
Gamida Cell Ltd |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1.Patients must be 2–25 years of age and at least 10kg
2.Patient is a candidate for allogeneic SCT for treatment of SCD or thalassemia:
a.Patient must have clinically severe SCD(eg. SS, SC or SBeta0 Thal) with at least one of the following clinical complications:
Recurrent painful events(at least 3 in the 2 years prior to enrollment) that cannot be explained by other causes. Pain may occur in typical sites associated with vaso-occlusive painful events and cannot be explained by causes other than sickle cell disease. Pain lasts at least 4 hours and requires parenteral narcotic treatment,equianalgesic dose of oral narcotics or parenteral nonsteroidal anti-inflamrnatory drugs. These painful events may be treated in any setting,but events managed at home will be considered only if there is documentation of the event in a clinical record that may be reviewed by an investigator. These events must occur despite adequate supportive care measures.
Acute chest syndrome with at least two episodes with the development of a new infiltrate on chest radiograph and/or having a perfusion defect demonstrable on a lung radioisotope scan within the past two years that required hospitalization, oxygen therapy, and RBC transfusion. These episodes must occur despite adequate supportive care measures.
Any combination of painful events and acute chest syndrome episodes that total three events within the two years before transplantation.
Any clinically significant neurologic event (stroke or hemorrhage) or any neurologic defect lasting more than 24 hours.
Patients on chronic PRBC transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (e.g. pain, stroke, and acute chest syndrome)
Abnormal cerebral MRI and abnormal cerebral MRA.
Abnormal Transcranial Doppler (TCD), as defined by a TCD velocity that exceeds 200 cm/sec by the non-imaging technique (or TCD measurement of >185 cm/sec by the imaging technique) measured at a minimum of two separate occasions one month or more apart
OR;
b.Patient must have thalassemia major requiring regular RBC transfusions
3.Patients must have a partially HLA-matched CBU. The unit must be HLA-matched at 4-6/6 HLA class I (HLA-A & HLA-B, low resolution) and II (HLA-DRB1, high resolution) loci with the subject. For patients weighing = 25 kg, the CBU must have a pre-cryopreserved, total CD34+ cell dose of =10x10^6 as well as a pre-cryopreserved total nucleated cell dose of =1.8x10^9. For patients weighing < 25 kg, the CBU must have a pre-cryopreserved, total CD34+ cell dose of =7x10^6 as well as a pre-cryopreserved total nucleated cell dose of =1.6x10^9.
4.The CBU will have undergone volume reduction (both plasma and red blood cell depletion) prior to cryopreservation.
5.Patients must have autologous stem cells harvested from bone marrow as a backup in case of graft failure.
6.Patients’ Performance score =70% by Lansky or Karnofsky performance status scale
7.Patient has sufficient physiologic reserves including:
Cardiac: Left ventricular ejection fraction (LVEF) > 50% by echocardiogram radionuclide scan or cardiac MRI; or LV shortening fraction > 26%.
Pulmonary: Pulse oximetry with a baseline O2 saturation of = 85% is required for all patients, DLCO > 60% of predicted for age (corrected for hemoglobin) for patients in whom pulmonary function testing can be performed.
Renal: Serum creatinine = 1.5 x upper limit of normal for age and GFR >
Exclusion criteria: 1.Evidence of uncontrolled bacterial, viral or fungal infections or severe concomitant diseases, which in the judgment of the Principal Investigator, indicate that the patient could not tolerate transplantation
2.Evidence of HIV infection or HIV positive serology
3.Evidence of active Hepatitis B, Hepatitis C or EBV as determined by serology or PCR
4.Pregnancy, as indicated by a positive serum human chorionic gonadotrophin (HCG) test, or lactation
5.Patients with 10/10 or 9/10 HLA-matched related family donor or unrelated donor able to donate
6.Severe alloimmunization with inability to guarantee a supply of adequate PRBC donors
7.Evidence of anti-HLA antibodies to the selected CordIn™ CBU (MFI>1000)
8.Prior allogeneic hematopoietic stem cell transplant within last 12 months .
9.Allergy to bovine, Gentamicin, or to any product which may interfere with the treatment
10.Psychologically incapable of undergoing bone marrow transplant (BMT) with associated strict isolation or documented history of medical non-compliance and/or psychiatric illness and/or social situations that would limit compliance with study requirements
11.Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Hemoglobinopathies MedDRA version: 18.0
Level: LLT
Classification code 10054658
Term: Thalassemia
System Organ Class: 100000004850
MedDRA version: 18.0
Level: LLT
Classification code 10040645
Term: Sickle cell disease NOS
System Organ Class: 100000004850
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Intervention(s)
|
Product Name: CordIn (CF cultured fraction and NF non-cultured fraction) Pharmaceutical Form: Suspension for injection INN or Proposed INN: allogeneic, umbilical cord blood-derived, ex vivo expanded, hematopoietic CD133+ cells Other descriptive name: ALLOGENEIC, UMBILICAL CORD BLOOD-DERIVED, EX VIVO EXPANDED, HEMATOPOIETIC CD133+ CELLS Concentration unit: Other Concentration type: not less then Concentration number: 1200000000- INN or Proposed INN: allogeneic, umbilical cord blood-derived, non-expanded, hematopoietic CD133- cells Other descriptive name: ALLOGENEIC, UMBILICAL CORD BLOOD-DERIVED, NON-EXPANDED, HEMATOPOIETIC CD133- CELLS Concentration unit: Other Concentration type: not less then Concentration number: 500000000-
|
Primary Outcome(s)
|
Secondary Objective: Cumulative incidence of transplant-related mortality at day 100 after transplantation Event-free survival at day 100 and 1 year after transplantation (patient’s death, autologous recovery, primary or secondary graft failure will be considered events for this endpoint) Overall survival at 1 year after transplantation (patient’s death will be considered the relevant event) RBC transfusion-free survival at 1 year in thalassemia patients Proportion of treatment free HbS = 30% at 1 year in SCD patients
|
Primary end point(s): 1. acute toxicities associated with the infusion of CordIn™, within 24 hours post-infusion 2. proportion of patients with donor-derived engraftment at 42 days following transplantation
|
Main Objective: Assess the acute toxicities associated with the infusion of CordIn, within 24 hours post-infusion Assess the proportion of patients with donor-derived engraftment at 42 days following transplantation
|
Timepoint(s) of evaluation of this end point: 1. 24 hours 2. day 42
|
Secondary Outcome(s)
|
Secondary end point(s): 1. Cumulative incidence of transplant-related mortality at day 100 after transplantation
2. Event-free survival at day 100 and 1 year after transplantation (patient’s death, autologous recovery, primary or secondary graft failure will be considered events for this endpoint)
3. Overall survival at 1 year after transplantation (patient’s death will be considered the relevant event)
4. RBC transfusion-free survival at 1 year in thalassemia patients
5. Proportion of treatment free HbS = 30% at 1 year in SCD patients
|
Timepoint(s) of evaluation of this end point: 1. day 100
2. day 100 and 1 year
3. 1 year
4. 1 year
5. 1 year
|
Secondary ID(s)
|
GCP#01.01.030
|
Source(s) of Monetary Support
|
Gamida Cell
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|